A Comparative Review of the Neuro- Psychopharmacology of Hallucinogen-Induced Altered States of Consciousness : The Uniqueness of Some Hallucinogens Ümit Sayin NeuroQuantology, June 2012, Volume 10, Issue 2, 316-340. eISSN 1303-5150 ABSTRACT Altered states of consciousness induced by hallucinogens (H-ASC) is still a vaguely understood phenomenon. Taken the diverse psychological effects they exert, the main mechanism of action of hallucinogens; LSD, ibogaine, THC, PCP, MDMA, methamphetamine, mescaline, psilocybin and DMT, of which psychological effects are discussed in the article, are not properly understood and explained by the modern methods of neuroscience due to the lack of vigorous research. The involvement of some receptors, such as, [...]
Lire la suiteEmerging from the dark side : new therapeutic applications of scheduled psychoactive substances Edward James, Thomas L Robertshaw & Andrew D Westwell Future Medical Chemistry, 2019 Doi : 10.4155/fmc-2018-0447 C - ISSN 1756-8919 “Public and mainstream scientific perceptions of these substances are shifting, and it is not difficult to envision a future in which MDMA and psilocybin play a role in contemporary medicine.” Keywords : harm reduction • healthcare • MDMA • positive psychology • psilocybin • psychoactive • psychotherapy The discovery and development of new medicines occupies years of painstaking and expensive scientific work, with multidisciplinary teams working together in the hope of developing a [...]
Lire la suiteBibliographie : Substances psychédéliques et traitement des Addictions, Dr Christian Sueur, GRECC, novembre 2019 Ayahuasca, LSD, Kétamine, Psilocybine, Ibogaine, MDMA, Salvia divinorum et Mescaline, et traitement des Addictions
Lire la suiteEmerging from the dark side : new therapeutic applications of scheduled psychoactive substances Edward James, Thomas L. Robertshaw & Andrew D. Westwell Future medicinal chemistry, February 2019 Doi : 10.4155/fmc-2018-0447 Keywords : harm reduction • healthcare • MDMA • positive psychology • psilocybin • psychoactive • psychotherapy The discovery and development of new medicines occupies years of painstaking and expensive scientific work, with multidisciplinary teams working together in the hope of developing a new chemical entity that outperforms the current standard of care within the chosen disease setting. Once optimized in the laboratory and achieving acceptable regulatory preclinical benchmarks, years of clinical evaluation are required [...]
Lire la suiteThe Prosocial Effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled Studies in Humans and Laboratory Animals Philip Kamilar-Britt and Gillinder Bedi Neuroscience & Biobehavioral Reviews, 2015, 57, 433–446. doi:10.1016/j.neubiorev.2015.08.016 Abstract Users of ±3,4-Methylenedioxymethamphetamine (MDMA; ‘ecstasy’) report prosocial effects such as sociability and empathy. Supporting these apparently unique social effects, data from controlled laboratory studies indicate that MDMA alters social feelings, information processing, and behavior in humans, and social behavior in rodents. Here, we review this growing body of evidence. In rodents, MDMA increases passive prosocial behavior (adjacent lying) and social reward while decreasing aggression, effects that may involve serotonin 1A receptor mediated oxytocin release interacting with vasopressin receptor [...]
Lire la suiteWhy Psychiatry Needs 3,4 Methylenedioxymeth-amphetamine : A Child Psychiatrist’s Perspective Ben SESSA Neurotherapeutics, 2017, 14, (3), 741-749. doi:10.1007/s13311-017-0531-1 Abstract Since the late 1980s the psychoactive drug 3,4-methylenedioxymethamphetamine (MDMA) has had a well-known history as the recreationally used drug ecstasy. What is less well known by the public is that MDMA started its life as a therapeutic agent and that in recent years an increasing amount of clinical research has been undertaken to revisit the drug’s medical potential. MDMA has unique pharmacological properties that translate well to its proposed agent to assist trauma-focused psychotherapy. Psychological trauma—especially that which arises early in life from child abuse—underpins many [...]
Lire la suiteHallucinogens and Their Therapeutic Use : A Literature Review Matthew J. BEGOLA, Jason E. SCHILLERSTROM Journal of Psychiatric Practice, 2019, 25, (5), 334–346 Doi : 10.1097/PRA.0000000000000409 The exploration of possible therapeutic benefitsof hallucinogenic substances has undergone a revitalization in the past decade. This literature review investigated the published literature regarding the psychotherapeutic uses of hallucinogens in psychiatric disorders. The results showed that a variety of substances have been evaluated in the treatment of psychiatric disorders, including ayahuasca, ibogaine, ketamine, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and psilocybin. The conditions treated ranged from depression to autism, with the largest volume of research dedicated to substance use disorders. [...]
Lire la suiteThe Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level–Dependent Resting State Functional Connectivity Robin L. Carhart-Harris, Kevin Murphy, Robert Leech, David Erritzoe, Matthew B. Wall, Bart Ferguson, Luke T.J. Williams, Leor Roseman, Stefan Brugger, Ineke De Meer, Mark Tanner, Robin Tyacke, Kim Wolff, Ajun Sethi, Michael A.P. Bloomfield, Tim M. Williams, Mark Bolstridge, Lorna Stewart, Celia Morgan, Rexford D. Newbould, Amanda Feilding, H. Val Curran, and David J. Nutt Biological Psychiatry, 2015, 78, 554-562. http://dx.doi.org/10.1016/j.biopsych.2013.12.015 ABSTRACT BACKGROUND : The compound 3,4-methylenedioxymethamphetamine (MDMA) is a potent monoamine releaser that produces an acute euphoria in most individuals. METHODS : [...]
Lire la suiteReceptor-Enriched Analysis of functional connectivity by targets (REACT) : A novel, multimodal analytical approach informed by PET to study the pharmacodynamic response of the brain under MDMA Ottavia Dipasquale, Pierluigi Selvaggi, Mattia Veronese, Anthony S. Gabay, Federico Turkheimer, Mitul A. Mehta NeuroImage, 2019, 195, 252–260 https://doi.org/10.1016/j.neuroimage.2019.04.007 A B S T R A C T One of the main limitations of pharmacological fMRI is its inability to provide a molecular insight into the main effect of compounds, leaving an open question about the relationship between drug effects and haemodynamic response. The aim of this study is to investigate the acute effects of 3,4-methylene-dioxymethamphetamine (MDMA) on functional [...]
Lire la suiteThe Role of MDMA Neurotoxicity in Anxiety Casey R. Guillot, Mitchell E. Berman and Brenton R. Abadie In : Neurotoxicity Syndromes, Chapter I ISBN: 978-1-60021-797-5 Editor: Linda R. Webster, pp. 1 - 36 © 2007 Nova Science Publishers, Inc. Abstract The drug 3,4-methylenedioxymethamphetamine (MDMA; Ecstasy) long has been considered a neurotoxin selective for serotonin (5-hydroxytryptamine; 5-HT) axons in rats and nonhuman primates. MDMA is also thought to have the potential to cause persistent serotonergic alterations in humans. Since the serotonin system is involved in the regulation of anxiety, researchers have proposed that recreational Ecstasy users may be at risk for the development of anxiety disorders and symptoms. [...]
Lire la suite